Skip to content

Patent Ductus Arteriosus (PDA) Screening Trial

The Role of Serial Echocardiography to Detect an Asymptomatic Patent Ductus Arteriosus (PDA) in Very Low Birth Weight (VLBW) Infants: A Pilot Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01031316
Enrollment
88
Registered
2009-12-14
Start date
2009-10-31
Completion date
2011-08-31
Last updated
2014-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ductus Arteriosus, Patent

Keywords

Echocardiography, Infant, Premature, Infant, Very Low Birth Weight

Brief summary

The ductus arteriosus directs blood away from the pulmonary circulation and toward the systemic circulation during fetal life, then closes after birth. In preterm infants the incidence of spontaneous closure decreases with gestational age. Patent ductus arteriosus (PDA) increases the risks of bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis (NEC). However, this association may not be a causal relationship. Echocardiography is required to diagnose PDA. However, routine screening echocardiograms lead to detection of asymptomatic PDAs, for which the benefit of therapy remains unproven. A randomized controlled trial has been designed in which 88 infants with birth weight less than or equal to 1250 grams and gestational age less than or equal to 30 weeks will be enrolled. The investigators' goal is to determine how screening echocardiography influences clinical management and outcomes in these infants.

Interventions

OTHERNondisclosure of screening echocardiogram results

Subjects will be randomized to nondisclosure of screening echocardiogram results.

OTHERDisclosure of screening echocardiogram results

Subjects will be randomized to disclosure of screening echocardiogram results.

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 72 Hours
Healthy volunteers
No

Inclusion criteria

* birth weight less than or equal to 1250 grams * gestational age less than or equal to 30 weeks * postnatal age less than or equal to 72 hours * have a guardian or acceptable surrogate capable of giving consent on his/her behalf

Exclusion criteria

* not considered viable * dysmorphic features or congenital malformations that adversely affect growth * have known or suspected congenital heart disease (other than PDA)

Design outcomes

Primary

MeasureTime frame
Number of days to regain birth weight.1-4 weeks

Secondary

MeasureTime frame
Necrotising enterocolitis (NEC) or >48 hours of NPO status for suspected NEC or feeding intolerance.3-6 months
Number of days to 120ml/kg/day of enteral feedings (full feeds).3-6 months
Ventilator days, number of days of positive airway pressure, and number of days in oxygen.3-6 months
Treatment for a PDA with indomethacin or surgical ligation.3-6 months
Confirmed or suspected sepsis.3-6 months
Worst stage of retinopathy of prematurity.3-6 months
Day of death or discharge.3-6 months
Worst grade of intraventricular hemorrhage and presence of periventricular leukomalacia.3-6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026